Some issues for implementing the requirements for good practices (GxP). Good distribution practice (GDP) (Part 2)

Authors

  • R. Gurzhii Ukrmedcert LLC

DOI:

https://doi.org/10.24959/nphj.21.47

Keywords:

good distribution practices, medicines, pharmaceutical market, pharmaceutical quality system

Abstract

Aim. To conduct a detailed study of the requirements of good distribution practice.

Materials and methods. The analysis of the current Guidelines on good practices (GxP), in particular the Guideline ST-N 42-5.0:2014 of the Ministry of Health of Ukraine “Medicines. Good Distribution Practice” was performed. Interpretations for the implementation of the requirements of good distribution practice based on the experience of audits of distribution companies for GDP compliance with the requirements were proposed.

Results and discussion. The dependence of the correct distribution of medicines on the personnel involved in this process has been studied, and the negative impact on the activity of a wholesale pharmaceutical company in case of non-compliance by the personnel with the relevant requirements has been determined. The benefits and risks that may arise during the distribution of medicines related to the staff have been identified. The requirements for the Authorized (Responsible) Person, the knowledge and experience that he must possess have been determined. The job description of the Authorized (Responsible) Person has been considered in detail. The responsibilities of the Authorized Person of a distribution company are listed.

Conclusions. The detailed analysis proposed will minimize the risks and errors that can lead to a negative impact on the quality of medicines. The appointment of the Authorized Person of a distribution company, the requirements imposed on him, the knowledge and experience that the Authorized Person must possess have been studied in detail. The advantages and risks of the personnel management of a distribution company have been identified.

Author Biography

R. Gurzhii, Ukrmedcert LLC

deputy director of Ukrmedcert LLC, Temporary WHO advisor, European GDP Association member

References

1. Guidelines on Good Distribution Practice of medicinal products for human use. (1.3.1994). Official Journal of the European Union, C 63, 4.

2. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001on the Community code relating to medicinal products for human use. (28.11.2001). Official Journal of the European Union, L 311, 67.

3. Guidelines of 7 March 2013 on Good Distribution Practice of Medicinal Products for Human Use. (8.3.2013). Official Journal of the European Union, C 68, 1.

4. Directive 2011/62/EC of the European Parliament and of the Council amending Directive2001/83/EC as regards the prevention of the entry into the legal supply chain of falsified medicinal products. (1.7.2011). Official Journal of the European Union, L 174, 74.

5. WHO expert committee on specifications for pharmaceutical preparations. (2006). WHO Technical Report Series, 937. Available at: https://apps.who.int/iris/bitstream/handle/10665/43443/WHO_TRS_937_eng.pdf

6. Recommendations on validation master plan in stall at ion and operation al qualification non-sterile process validation cleaning validation. (2007). PIC/S, PI 006-3, 26 р.

7. Ministerstvo okhorony zdorov’ia Ukrainy. (2014). Nastanova ST-N MOZU 42-5.0:2014 “Likars’ki zasoby. Nalezhna praktyka dystrybutsii”. Kyiv, 51.

8. Ministerstvo okhorony zdorov’ia Ukrainy. (2009). Nastanova ST-NMOZU 42-5.0:2008 “Likars’ki zasoby. Nalezhna praktyka dystrybutsii”. Kyiv, 18.

9. Ministerstvo okhorony zdorov’ia Ukrainy. (2014). Nastanova ST-NMOZU 42-1.0:2014 “Likars’ki zasoby. Nalezhna praktyka dystrybutsii”. Kyiv, 46.

10. Ministerstvo okhorony zdorov’ia Ukrainy. (2016). Nastanova ST-N MOZU 42-4.0:2016 “Likars’ki zasoby. Nalezhna praktyka dystrybutsii”. Kyiv, 357.

11. TRS 1025 - Annex 7: Good storage and distribution practices for medical products. (2020). WHO Technical Report Series, 1025. Available at:
https://www.who.int/publications/m/item/trs-1025-annex-7-gdp-medical-products.

Published

2021-02-01

Issue

Section

Organization and Economy of Pharmacy